Status and phase
Conditions
Treatments
About
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other inclusion/exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
200 participants in 4 patient groups
Loading...
Central trial contact
DWTI CTA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal